DENALI THERAPEUTICS INC (DNLI) Stock Analyst Earnings Estimates
NASDAQ:DNLI - Nasdaq - US24823R1059 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 48.7M -85.49% | 108.5M 122.79% | 330.531M 204.64% | 8.874M -97.32% | 34.536M 289.18% | 169.96M 392.12% | 408.6M 140.41% | 646.27M 58.17% | 885.47M 37.01% | 1.233B 39.25% | 2.017B 63.58% | 2.122B 5.21% | |
| EBITDA YoY % growth | -287.2M -503.37% | -330.3M -15.01% | -179.973M 45.51% | -534.182M -196.81% | -525.85M 1.56% | -473.931M 9.87% | -316.04M 33.32% | -39.286M 87.57% | 374.29M 1,052.72% | 982.75M 162.56% | 1.46B 48.56% | 1.573B 7.74% | |
| EBIT YoY % growth | -295.8M -571.77% | -340.7M -15.18% | -196.699M 42.27% | -518.173M -163.43% | -562.236M -8.50% | -480.416M 14.55% | -307.687M 35.95% | -46.328M 84.94% | 322.54M 796.21% | 698.96M 116.70% | 1.32B 88.85% | 1.691B 28.11% | |
| Operating Margin | -607.39% | -314.01% | -59.51% | -5,839.23% | -1,627.97% | -282.66% | -75.30% | -7.17% | 36.43% | 56.69% | 65.44% | 79.69% | |
| EPS YoY % growth | -2.39 -1,019.23% | -2.60 -8.79% | -1.08 58.46% | -2.76 -155.51% | -3.09 -11.86% | -2.52 18.37% | -0.75 70.05% | -0.13 82.77% | 1.94 1,590.20% | 3.51 81.23% | 7.29 107.46% | 9.69 32.99% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.82 5.04% | -0.79 -0.89% | -0.79 -33.26% | -0.71 -13.04% | -0.81 0.55% | -0.80 -1.10% | -0.80 -1.19% | -0.79 -10.29% | -0.78 4.56% |
| Revenue Q2Q % growth | 10.914M | 1.821M | 1.821M | 22.695M | 10.067M -7.76% | 3.437M 88.74% | 7.65M 320.10% | 11.924M -47.46% | 16.249M 61.41% |
| EBITDA Q2Q % growth | -111.731M 3.55% | -105.93M 18.57% | -100.92M 10.28% | -104.172M 10.82% | -125.6M -12.41% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -146.863M -10.78% | -141.21M -6.77% | -138.52M -18.81% | -116.524M 5.41% | -142.469M 2.99% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.63 12.50% | -0.63 | 0.00 | -0.50% |
| Q2 2024 Q2Q % growth | -0.59 -145.38% | -0.70 | 0.11 | 15.61% |
| Q1 2024 Q2Q % growth | -0.78 2.50% | -0.72 | -0.06 | -8.80% |
| Q4 2023 Q2Q % growth | -0.86 -14.67% | -0.82 | -0.04 | -4.84% |
| Q3 2023 Q2Q % growth | -0.72 14.29% | -0.82 | 0.10 | 12.04% |
| Q2 2023 Q2Q % growth | 1.30 370.83% | -0.70 | 2.00 | 286.35% |
| Q1 2023 Q2Q % growth | -0.80 -50.94% | -0.72 | -0.08 | -11.37% |
| Q4 2022 Q2Q % growth | -0.75 -20.97% | -0.81 | 0.06 | 6.94% |
| Q3 2022 Q2Q % growth | -0.84 -21.74% | -0.82 | -0.02 | -2.15% |
| Q2 2022 Q2Q % growth | -0.48 4.00% | -0.56 | 0.08 | 14.30% |
| Q1 2022 Q2Q % growth | -0.53 8.62% | -0.52 | -0.01 | -2.25% |
| Q4 2021 Q2Q % growth | -0.62 -132.46% | -0.42 | -0.20 | -46.88% |
| Q3 2021 Q2Q % growth | -0.69 -27.78% | -0.48 | -0.21 | -42.76% |
| Q2 2021 Q2Q % growth | -0.50 10.71% | -0.42 | -0.08 | -19.83% |
| Q1 2021 Q2Q % growth | -0.58 -5.45% | -0.35 | -0.23 | -65.09% |
| Q4 2020 Q2Q % growth | 1.91 441.07% | 0.01 | 1.90 | 23,968.75% |
| Q3 2020 Q2Q % growth | -0.54 -12.50% | 2.64 | -3.18 | -120.47% |
| Q2 2020 Q2Q % growth | -0.56 8.20% | -0.61 | 0.05 | 8.65% |
| Q1 2020 Q2Q % growth | -0.55 -34.15% | -0.58 | 0.03 | 5.40% |
| Q4 2019 Q2Q % growth | -0.56 | -0.59 | 0.03 | 4.93% |
| Q3 2019 Q2Q % growth | -0.48 | -0.57 | 0.09 | 16.41% |
| Q2 2019 Q2Q % growth | -0.61 | -0.47 | -0.14 | -29.61% |
| Q1 2019 Q2Q % growth | -0.41 | -0.41 | 0.00 | 0.34% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -100.00% | 9.18M | -9.18M | -100.00% |
| Q2 2024 Q2Q % growth | -100.00% | 15.803M | -15.803M | -100.00% |
| Q1 2024 Q2Q % growth | -100.00% | 14.304M | -14.304M | -100.00% |
| Q4 2023 Q2Q % growth | -100.00% | 8.532M | -8.532M | -100.00% |
| Q3 2023 Q2Q % growth | 1.267M -64.81% | 11.404M | -10.137M | -88.89% |
| Q2 2023 Q2Q % growth | 294.123M 460.23% | 13.727M | 280.396M | 2,042.66% |
| Q1 2023 Q2Q % growth | 35.141M -16.53% | 29.294M | 5.847M | 19.96% |
| Q4 2022 Q2Q % growth | 10.3M -17.60% | 13.378M | -3.078M | -23.01% |
| Q3 2022 Q2Q % growth | 3.6M -32.08% | 14.762M | -11.162M | -75.61% |
| Q2 2022 Q2Q % growth | 52.5M 129.26% | 44.779M | 7.721M | 17.24% |
| Q1 2022 Q2Q % growth | 42.1M 432.91% | 26.206M | 15.894M | 60.65% |
| Q4 2021 Q2Q % growth | 12.5M -96.05% | 45.721M | -33.221M | -72.66% |
| Q3 2021 Q2Q % growth | 5.3M -43.62% | 30.887M | -25.587M | -82.84% |
| Q2 2021 Q2Q % growth | 22.9M 294.83% | 28.474M | -5.574M | -19.58% |
| Q1 2021 Q2Q % growth | 7.9M 119.44% | 32.256M | -24.356M | -75.51% |
| Q4 2020 Q2Q % growth | 316.8M 6,640.43% | 79.773M | 237.027M | 297.13% |
| Q3 2020 Q2Q % growth | 9.4M -30.88% | 384.98M | -375.58M | -97.56% |
| Q2 2020 Q2Q % growth | 5.8M 38.10% | 3.859M | 1.941M | 50.30% |
| Q1 2020 Q2Q % growth | 3.6M -14.29% | 5.107M | -1.507M | -29.51% |
| Q4 2019 Q2Q % growth | 4.7M | 8.791M | -4.091M | -46.54% |
| Q3 2019 Q2Q % growth | 13.6M | 9.514M | 4.086M | 42.95% |
| Q2 2019 Q2Q % growth | 4.2M | 3.999M | 201K | 5.03% |
| Q1 2019 Q2Q % growth | 4.2M | 9.301M | -5.101M | -54.84% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 4.28% | -10.31% | 3.08% | -2.34% |
| Revenue | -3.46% | -12.51% | 51.3% | -49.4% |